What Can Ford’s River Rouge Plant Teach Us About Vertical Integration in Healthcare?

Posted by Brian Chapman on August 28, 2018

This blog post was originally published on the Medtech Conference (AdvaMed) blog

For anyone who grew up in Michigan, the Ford River Rouge Plant is legendary, in both the scale of its ambition and its dramatic fall as the auto industry matured. Built outside of Detroit in 1928, it was the largest manufacturing facility in the world at its peak, with 16 million square feet and 100,000 employees. Unloaded on the docks of the River Rouge were iron ore, coal and other raw materials. Rolling out the other side of the factory were fully finished cars. In between was a steel mill that boasted its own coal power plant. By 2018 the factory was idled and now has a museum, a light truck assembly facility and a very large parking lot.


>
Read More

How the Johnson & Johnson Medical Devices Companies Are Responding to the Changing Healthcare Landscape

Posted by Brian Chapman on February 27, 2018

This post is the second in a series on the evolution of the medtech commercial model.

The healthcare industry is in the midst of an evolution from volume to value, but it will be a long time before we can say that the old model is behind us. As I wrote in my previous post, this evolution isn’t an overnight transformation but rather a slow burn. This is forcing medtech companies to have “a foot in both worlds:” They must continue partnering with clinical stakeholders while addressing the emerging needs of commercial stakeholders, but at a pace that's in sync with their own evolution. Sometimes that pace is extremely rapid and sometimes feeling a bit more glacial.  


>
Read More

Don’t Call It a Transformation: Four Takeaways From The Medtech Conference

Posted by Brian Chapman on February 20, 2018

This post is the first in a series on the evolution of the medtech commercial model.


I facilitated a panel last fall at The MedTech Conference (formerly the AdvaMed conference) and have continued to think about it. Subsequent conversations with leaders have made me want write down a few thoughts from the day. The panel was called “Driving Growth Through New Commercial Strategies” with medtech experts including Tim Schmid, chief strategic customer officer at Johnson & Johnson Medical Device Companies; Joe Gasque, CMO for the U.S. and Canada at GE Healthcare; and Vince Wong, vice president of strategy and communications at Roche Diagnostics. This group packed the room, and in my humble opinion, the audience seemed pretty engaged.


>
Read More

What to Expect in Medtech for 2018

Posted by Brian Chapman on January 25, 2018

Earlier this year, I was interviewed by Ashley Yeo, the executive editor of In Vivo. He wanted some thoughts about what was on the mind of medtech executives. It got me thinking about a couple of key themes: 

>
Read More

M&A in Medtech: How to Ensure That Scale Becomes a Competitive Advantage

Posted by Brian Chapman on September 29, 2017

Sudhanshu Bhatnagar co-wrote this blog post with Brian Chapman. It was originally published in The MedTech Strategist “Best of the Best 2016-2017 Special Edition” in September 2017.

After Michael Phelps won his 23rd Olympic gold medal in Rio de Janeiro last year, social media was rife with infographics on how his anatomy and size (height, wingspan and, falsely, even his “double” lung capacity) destined him to be a great swimmer. Yes, he’s tall, but so are his competi­tors. Such incomplete descriptions fail to mention that his skill, technique, methodical training and dedication to goals are what set him apart.


>
Read More